In this episode, we sat down with Dr. Arun Menawat, Chairman and CEO of Profound Medical. 

Profound is commercializing the TULSA-PRO system, an alternative approach to prostate cancer treatment that uses MRI-guided thermal ultrasound to target and eliminate cancerous tissue without surgical incisions. 

Before joining Profound in 2016, Arun served as the Chairman and CEO of Novadaq Technologies for 13 years, guiding the company from a startup to one of the fastest-growing, NASDAQ-listed medical technology businesses with a market cap exceeding one billion USD. Earlier in his career, Arun served as President of Cedara Software, a company that developed the industry’s first medical imaging software platform. Today, it’s part of IBM’s Watson Health.

In this interview, Arun shares insights on building credibility with physicians, the strategic approach to clinical trials that led to their recent Medicare reimbursement coverage, and his vision for transforming the future of surgery beyond prostate cancer.

In this episode, we sat down with Claire Dixon, CEO of Neuraura.

Neuraura is developing LoOop, an over-the-counter wearable that targets PCOS through low-frequency electrical stimulation.

Claire brings over 25 years of international leadership experience to her role as co-founder and CEO of Neuraura. With a master's degree in engineering from Cambridge and an MBA from Harvard, she spent 15 years as a strategic consultant to capital-intensive businesses before transitioning to entrepreneurship. She was recently named among the “Top 200 Trailblazing Leaders in Women's Health and femtech” by Women of Wearables.

In this interview, Claire shares insights on navigating regulatory pathways, designing for real user needs, and building strategic partnerships to bring innovative women's health solutions to market through a direct-to-consumer approach.

In this episode, we sat down with Vicky Demas, CEO of identifeye HEALTH (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.

Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.

In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.

In this episode, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women’s homes. 

Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.

In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.

In this episode, we sat down with Ryan Rhodes, CEO of EDAP TMS. EDAP is changing prostate cancer treatment through Focal One, a robotic high-intensity focused ultrasound (HIFU) system that doesn’t require the use of surgery or radiation. 

Ryan has over 30 years of experience in market development, with two decades focused on medical robotics. Before EDAP, Ryan was CEO of Restoration Robotics, where he guided the company to a successful merger with Venus Concept. He spent 13+ years at Intuitive Surgical, establishing the global Urology franchise, which became the company’s entry point for broader adoption of the da Vinci system. He also spent 11 years at Ethicon (J&J) in sales, marketing, and market development.

In this interview, Ryan challenges founders to ask: Are you creating a scalable medtech solution or a product with limited growth potential? He unpacks why standardization and scalability are critical for adoption, how clinical data fuels credibility and reimbursement, and why early adopters take the biggest risks — but also reap the biggest rewards.

In this episode, we sat down with Kirk Huntsman, CEO of Vivos, a company commercializing a non-invasive, FDA-cleared oral appliance designed to treat obstructive sleep apnea (OSA).

Kirk is a seasoned healthcare entrepreneur with a track record for scaling and exiting successful businesses. He founded Dental One, growing it into one of the largest dental service organizations (DSO) in the U.S., with over 165 practices across 15 states. After selling the company to MSD Capital, he led ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. He later built and exited Xenith Practices, another DSO, and founded Ortho Ventures, focusing on pediatric oral appliances. Now as CEO of Vivos, Kirk and his team are developing and commercializing proprietary treatments for sleep-related breathing disorders, offering patients an FDA-cleared alternative to CPAP therapy.

In this interview, Kirk talks about his go-to-market strategy, the importance of credibility markers, the complexity of industry partnerships, and the challenges he faced pursuing an IPO.

In this episode, we sat down with Caitlin Morse, CEO and co-founder of BrainSpace, who has a decade of experience spanning medtech consulting, product development, and strategic advising. 

BrainSpace is developing an innovative precision drainage system with continuous ICP monitoring designed to automate cerebrospinal fluid management for patients recovering from strokes, traumatic brain injuries, and neurosurgery. 

In this interview, Caitlin shares her advice on assessing the viability of a medtech idea, tells the story of how her prototype won over stakeholders, and discusses navigating the development phase while balancing clinical and regulatory demands.

In this episode, we had an insightful discussion with Drs. Asha Parekh and Adam Power, co-founders of Front Line Medical Technologies. The company's COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System) is a compact, minimally invasive device, designed for temporary aortic occlusion in trauma situations. 

Asha has a PhD in Biomedical Engineering from Western University, and combines technical expertise with entrepreneurial leadership. Adam is an academic and practicing vascular surgeon at Western University, with extensive training from institutions including Dalhousie, McMaster, and Mayo Clinic.

In this interview, they discuss how their clinical-engineer partnership accelerated development, their approach to clinical studies for regulatory clearance across multiple geographies, and their strategic decision to avoid VC funding during early development—and how that decision paid off.

In this episode, we sat down with Kelly Huang, President and CEO of Elucid. Elucid has developed a platform that uses AI to analyze cardiac CT scans to provide a detailed, non-invasive assessment of a patient’s arterial plaque. Kelly's journey spans nearly 30 years of leadership in healthcare, with expertise in driving innovation and growth across medical devices, diagnostics, health IT, and consumer health. Before Elucid, he served as COO at Cardea Bio, leading its successful acquisition by Paragraf, and as CEO of Obalon Therapeutics, where he introduced noninvasive medical devices to expand treatment options for physicians. Kelly's career also includes senior roles at L-Nutra, Nestlé/Galderma, Endo Pharmaceuticals, and Johnson & Johnson.

In this interview, Kelly shares advice on how to successfully bring novel devices to market, secure reimbursement, and drive adoption by focusing on the essentials—collaboration, trust, robust data, and transparency.

In this episode, we had an insightful chat with Nitin Salunke, President and CEO of Supira Medical, a Shifamed portfolio company. Supira is developing a catheter-based heart pump that provides hemodynamic support for patients undergoing high-risk heart procedures. Before Supira, Nitin was Vice President of R&D at Medtronic Neurovascular, overseeing global product development. He has also held leadership roles at Altura Medical, Cordis Corp (then a Johnson & Johnson company), and W.L. Gore & Associates. Nitin holds a PhD in Mechanical Engineering and is an inventor and co-author on many patents and publications.

In this interview, Nitin shares the philosophy that guided his journey as CEO of Supira, his strategy to evaluate and address major risk factors in medtech, how to generate value for all stakeholders—patients, physicians, and investors, and his formula for creating a next-gen medical device.